The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma

被引:32
作者
Ciolli, Stefania [1 ]
Leoni, Franco [1 ]
Casini, Cinzia [1 ]
Breschi, Carla [2 ]
Santini, Valeria [1 ]
Bosi, Alberto [1 ]
机构
[1] Careggi Hosp, Dept Haematol, Florence, Italy
[2] Ceppo Hosp, Dept Oncol, Pistoia, Italy
关键词
myeloma; bortezomib; dexamethasone; thalidomide; liposomal doxorubicin;
D O I
10.1111/j.1365-2141.2008.07147.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relapsed/refractory myeloma has a poor outcome because of multi-drug resistance, patient low-performance status and toxicity of conventional chemotherapy. To improve results, standard chemotherapeutics and drugs targeting the microenvironment are applied at the same time. Bortezomib, by inhibiting proteasome function, may enhance chemosensitivity to other drugs and overcome drug-resistance. Notably, doxorubicin and bortezomib may reciprocally increase their efficacy. Thus, to improve outcome whilst minimizing therapy-related toxicity, liposomal doxorubicin was added to a bortezomib-based combination. From January 2004, relapsed/refractory myeloma patients referred to our Institution received bortezomib 1.0 mg/m(2) i.v. twice weekly for 2 weeks in a 28-d cycle for up to six cycles, oral dexamethasone 24 mg with the standard scheduling and thalidomide 100 mg continuously (VTD). From January 2005, liposomal doxorubicin, 50 mg/m(2) (30 mg/m(2) for patients older than 75 years), was added on day 4 of each cycle [VTD plus Myocet (MyVTD)]. In total, 70 patients were treated: 28 received VTD and 42 MyVTD. Baseline demographic and clinical characteristics were similar between the two groups. Toxicity was manageable although more pronounced with MyVTD. The overall response rate (81% vs. 50%, P = 0.009), time to progression (19 vs. 11 months, P = 0.01) and progression-free survival (15 vs. 8 months, P = 0.001) were significantly higher with MyVTD regimen, suggesting an improved quality of response.
引用
收藏
页码:814 / 819
页数:6
相关论文
共 50 条
[31]   Bortezomib in combination with thalidomide and dexamethasone - a successful treatment regimen in refractory extramedullary multiple myeloma [J].
Dytfeld, Dominik ;
Matuszak, Magdalena ;
Lewandowski, Krzysztof ;
Komarnicki, Mieczyslaw .
ANNALS OF HEMATOLOGY, 2008, 87 (03) :253-254
[32]   Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma [J].
Dominik Dytfeld ;
Magdalena Matuszak ;
Krzysztof Lewandowski ;
Mieczysław Komarnicki .
Annals of Hematology, 2008, 87 :253-254
[33]   Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial [J].
Jakubowiak, Andrzej J. ;
Griffith, Kent A. ;
Reece, Donna E. ;
Hofmeister, Craig C. ;
Lonial, Sagar ;
Zimmerman, Todd M. ;
Campagnaro, Erica L. ;
Schlossman, Robert L. ;
Laubach, Jacob P. ;
Raje, Noopur S. ;
Anderson, Tara ;
Mietzel, Melissa A. ;
Harvey, Colleen K. ;
Wear, Sandra M. ;
Barrickman, Jennifer C. ;
Tendler, Craig L. ;
Esseltine, Dixie-Lee ;
Kelley, Susan L. ;
Kaminski, Mark S. ;
Anderson, Kenneth C. ;
Richardson, Paul G. .
BLOOD, 2011, 118 (03) :535-543
[34]   Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma [J].
Rosinol, Laura ;
Hebraud, Benjamin ;
Oriol, Albert ;
Colin, Anne-Laurene ;
Tamayo, Rafael Rios ;
Hulin, Cyrille ;
Blanchard, Maria Jesus ;
Caillot, Denis ;
Sureda, Anna ;
Hernandez, Miguel Teodoro ;
Arnulf, Bertrand ;
Mateos, Maria-Victoria ;
Macro, Margaret ;
San-Miguel, Jesus ;
Belhadj, Karim ;
Lahuerta, Juan Jose ;
Garelik, M. Brigid ;
Blade, Joan ;
Moreau, Philippe .
FRONTIERS IN ONCOLOGY, 2023, 13
[35]   Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma [J].
Zhang, Yongqing ;
Liu, Hongjuan ;
Chen, Xiequn ;
Bai, Qingxian ;
Liang, Rong ;
Shi, Bing ;
Liu, Lihui ;
Tian, DengMei ;
Liu, Mingjuan .
PATHOLOGY & ONCOLOGY RESEARCH, 2014, 20 (04) :987-995
[36]   Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study [J].
Zervas, K ;
Dimopoulos, MA ;
Hatzicharissi, E ;
Anagnostopoulos, A ;
Papaioannou, A ;
Mitsouli, C ;
Panagiotidis, P ;
Korantzis, J ;
Tzilianos, M ;
Maniatis, A .
ANNALS OF ONCOLOGY, 2004, 15 (01) :134-138
[37]   Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy [J].
Sonneveld, Pieter ;
Hajek, Roman ;
Nagler, Arnon ;
Spencer, Andrew ;
Blade, Joan ;
Robak, Tadeusz ;
Zhuang, Sen H. ;
Harousseau, Jean-Luc ;
Orlowski, Robert Z. .
CANCER, 2008, 112 (07) :1529-1537
[38]   The Efficacy and Safety of Bortezomib and Dexamethasone as a Maintenance Therapy in Patients With Advanced Multiple Myeloma Who Are Responsive to Salvage Bortezomib-Containing Regimens [J].
Benevolo, Giulia ;
Larocca, Alessandra ;
Gentile, Massimo ;
Pregno, Patrizia ;
Gay, Francesca ;
Botto, Barbara ;
Frairia, Chiara ;
Evangelista, Andrea ;
Morabito, Fortunato ;
Boccadoro, Mario ;
Vitolo, Umberto ;
Palumbo, Antonio .
CANCER, 2011, 117 (09) :1884-1890
[39]   Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma [J].
Azarm, Taleb ;
Akbari, Mojtaba ;
Azarm, Arezo ;
Mohager, Hamid .
JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2012, 17 (01) :8-14
[40]   Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone [J].
Du, Juan ;
Yuan, Zhengang ;
Zhang, Chunyang ;
Fu, Weijun ;
Jiang, Hua ;
Chen, Baoan ;
Hou, Jian .
LEUKEMIA RESEARCH, 2010, 34 (11) :1453-1458